Literature Review: Identification and Surveillance of Rare Relapse-Initiating Stem Cells during Complete Remission Post-Transplantation

Needs Statement

Attending physicians, advanced practice providers, fellows, residents, and medical students in the fields of hematology-oncology and bone marrow transplantation need to receive regular updates on advances in hematopoietic stem cell transplantation and cellular therapies. Through reviews and appraisal of recent clinical trials, the series aims to expand the knowledge of learners, facilitate improvements in the treatment of immunodeficiencies and hematological malignancies and disorders, enhance the quality of hematology-oncology care, reduce treatment-related morbidity and mortality related to stem cell transplant, and improve patient outcomes.

Educational Objectives

At the conclusion of the session, the participants should be able to:

• Appraise the study methodology: flow sorting of hematopoietic stem cells and mutational screening for persistence of rare cancer stem cells.
• Explain how mutational screening of hematopoietic stem and progenitor cells after stem cell transplantation enhanced the sensitivity of measurable residual disease (MRD).

Target Audience

Accreditation/Credit Designation

Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Baylor College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy

Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CE activities that are scientifically based, accurate, current, and objectively presented.

In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships at the time of the activity or within 24 months prior.

In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME's validation of clinical content statements.

BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.

All of the relevant financial relationships listed for these individuals have been mitigated.